A Pilot Trial of Nivolumab and Ipilimumab in Combination With Radiotherapy in Patients With Locally Advanced Head and Neck Cancer; CA209-931
Phase of Trial: Phase 0
Latest Information Update: 23 Oct 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- 08 Oct 2018 Status changed from active, no longer recruiting to recruiting.
- 31 Aug 2018 Biomarkers information updated
- 17 Jul 2018 Status changed from recruiting to active, no longer recruiting.